LL-37: the human antimicrobial peptide up for FDA review
Last updated: October 27, 2026 · 8 min read · By the Grey Peptides Editorial Board
- LL-37 is the only human cathelicidin, a natural peptide that kills microbes and signals to the immune system.
- On leg ulcers, a small trial looked promising but the larger phase 2b trial did not improve healing overall.
- FDA says compounded LL-37 may provoke immune reactions, and that animal and cell findings suggest harm to male reproduction and possible tumour promotion.
- It is one of five peptides FDA plans to put before its compounding advisory committee before the end of February 2027. It is not FDA-approved.
What LL-37 is
Cathelicidins are a family of antimicrobial peptides, and LL-37 is the only cathelicidin-derived antimicrobial peptide found in humans 1. A 2012 review describes it as antibacterial, antifungal and antiviral, and also as a signal that attracts immune cells, modulates immunity, promotes wound healing and new blood vessels, and affects cell death (review) 2. Its precursor, hCAP18, is found in every human organ examined, highest in the gut and brain (laboratory study) 1.
It is part of everyday defence. Cells lining the urinary tract produce and release it rapidly on contact with bacteria, it appears in human urine, and mice lacking the mouse version (CRAMP) were less protected against urinary infection (animal and human study) 3.
The wound trials
LL-37's main clinical test has been on chronic wounds. In a 2014 trial run by the developer, Pergamum, 34 people with hard-to-heal venous leg ulcers applied topical LL-37 at one of three strengths or placebo for four weeks; healing-rate constants for the two lower strengths were about six and three times placebo's (significant for the lowest strength, p = 0.003; not for the middle, p = 0.088), ulcers shrank by 68% and 50%, and the highest strength did no better than placebo (randomised trial) 4.
The larger follow-up, HEAL LL-37, a phase 2b trial with authors from the developer, Promore Pharma, randomised 148 patients with the same kind of ulcers to two strengths or placebo alongside compression. Across the whole group, LL-37 did not significantly improve healing; a post hoc analysis found benefit in wounds of at least 10 cm², a subgroup result that needs its own trial (randomised trial) 5. In a trial in Jakarta in mildly infected diabetic foot ulcers, LL-37 cream improved granulation, the growth of healthy wound tissue, at every weekly check, but did not lower inflammation markers or bacterial colonisation (randomised trial) 6.
| Trial | Patients | Result |
|---|---|---|
| Phase 1/2, venous leg ulcers (2014) | 34 | Only the lowest strength (0.5 mg/mL) healed significantly faster than placebo; the middle strength's faster rate was not significant, and the highest did no better |
| HEAL LL-37, phase 2b, venous leg ulcers (2021) | 148 | No significant healing benefit overall; post hoc signal in larger wounds |
| Diabetic foot ulcers, Jakarta (2023) | Not given in abstract | Better granulation; no change in inflammation markers or bacteria |
| Oral recombinant LL-37, COVID-19 (2023) | 238, open label | Faster negative viral test (9.8 vs 14.0 days) |
So a promising small trial was followed by a larger one that found no overall benefit 5, and in the small trial the highest strength worked least 4.
LL-37 by mouth in COVID-19
A different product, a genetically modified Lactococcus bacterium that delivers LL-37 in the gut, was tested in 238 adults hospitalised with an Omicron variant. In an open-label, randomised, placebo-controlled single-centre study, it shortened the time to a negative viral test to 9.8 days against 14.0 with placebo, with no severe adverse events; the open-label design limits how far the result can be trusted (randomised, open-label trial) 7. That product is not what is sold online as LL-37 powder, and its result says nothing about injecting synthetic LL-37.
When more LL-37 is not better
Because LL-37 is a powerful immune signal, too much of it, or the wrong form, can cause harm. People with rosacea have abnormally high cathelicidin in their facial skin, processed into different fragments than in healthy skin; injecting those fragments into mouse skin increased inflammation, and mice lacking the gene confirmed its role (human tissue and animal study) 8. In 109 breast cancers, LL-37's precursor tracked a growth receptor (ERBB2) and, in oestrogen-receptor-positive tumours, lymph-node spread, and LL-37 increased breast cancer cell migration in the laboratory, with overexpression promoting metastasis in mice (laboratory and animal study) 9. In cultured human microglia and astrocytes, it triggered release of inflammatory signals (laboratory study) 1.
Not every finding points one way: in rats with heat stroke, LL-37 reduced gut injury and system-wide inflammation (animal study) 10. The findings differ with tissue and setting.
LL-37 and autoimmunity: the psoriasis story
LL-37's strongest link to disease runs through psoriasis. A 2007 study in Nature found that LL-37 is the key factor that lets a type of immune cell, the plasmacytoid dendritic cell, react to the body's own DNA: LL-37 binds self-DNA into condensed aggregates that these cells take up and mistake for a viral signal, triggering interferon production, a mechanism the authors linked to breaking tolerance in psoriasis (laboratory study with patient samples) 11.
LL-37 is now counted among the autoantigens of psoriasis. A 2020 review lists cathelicidin LL-37 as one of four psoriasis autoantigens discovered since 2014, with self-reactive T cells against it found in a number of patients with moderate-to-severe plaque psoriasis, and autoantibodies against it strongly associated with psoriatic arthritis (review) 12. FDA separately lists possible immunogenicity among its concerns for compounded LL-37 13.
What FDA says, as of October 27, 2026
FDA's list of bulk substances that may present significant safety risks in compounding includes cathelicidin LL-37. FDA says compounded drugs containing it may pose a risk of immunogenicity for certain routes of administration and may have complexities with peptide-related impurities and characterisation of the active ingredient; that it lacks sufficient safety information to know whether the drug would cause harm in humans; and that nonclinical findings suggest detrimental effects on male reproduction and that it can promote tumours in some tissues 13.
FDA lists LL-37 in that page's table of nominations withdrawn by the nominators, not among substances currently in Category 2 13. FDA's meeting page (content current as of April 15, 2026) says its Pharmacy Compounding Advisory Committee will discuss five bulk drug substances, LL-37 with GHK-Cu, dihexa acetate, melanotan II and pegylated mechano growth factor, at a meeting before the end of February 2027 that "will be scheduled in the coming months" 14. FDA's meeting pages describe advisory committee votes as non-binding recommendations 15; our PCAC hub covers the July 2026 meeting.
The other four peptides in the review
LL-37 shares the coming review with four very different compounds: GHK-Cu, a copper-binding tripeptide; dihexa acetate, an angiotensin-derived compound; melanotan II, a tanning and sexual-function melanocortin agonist; and pegylated mechano growth factor 14. Our pages cover three of them in depth: the GHK-Cu entry and injectable GHK-Cu guide, the dihexa safety article, and the melanotan II entry.
What to watch for at the meeting
When the meeting is scheduled, FDA will publish briefing documents. For LL-37, the concerns FDA has already listed suggest what it will weigh: whether the route proposed, topical or injected, changes the immunogenicity risk; whether impurities and characterisation can be controlled; and how to weigh the nonclinical male-reproduction and tumour-promotion findings against the modest human wound data 13. We will cover the briefing and any vote on our PCAC hub and in the Wire.
Why immunogenicity matters for a human peptide
It may seem odd that a peptide the body already makes could provoke an immune reaction. FDA's concern is tied to the route of administration and to peptide-related impurities and characterisation of the ingredient 13, and in psoriasis LL-37 itself is a target of self-reactive T cells and autoantibodies 12. Our guide to how peptides are made explains how impurities arise.
LL-37 and vitamin D
LL-37 often appears in discussions of vitamin D and infection. The human data are not simple: in serum from 95 patients with tuberculosis, 86% had insufficient vitamin D, but vitamin D status did not correlate with LL-37 levels, and higher LL-37 went with more severe disease markers (observational study) 16. Measuring or raising LL-37 is not an established way to prevent infection.
Status and sport
LL-37 has no FDA approval. WADA's 2026 Prohibited List does not name it; its S0 section prohibits substances not covered elsewhere "with no current approval by any governmental regulatory health authority for human therapeutic use" 17. Tested athletes should ask their anti-doping organisation. Our WADA hub explains S0.
Questions to ask before using LL-37
- Has it been tested in people for what I want to use it for? Its best evidence, on leg ulcers, missed its main goal in the larger trial.
- Is the product topical or injectable? FDA's immunogenicity concern is route-dependent.
- Do I have rosacea, psoriasis or psoriatic arthritis, or a history of cancer? The rosacea, psoriasis and breast-cancer findings above are from tissue, laboratory and animal work.
- What is actually in the vial, and has it been tested for impurities?
- Am I subject to anti-doping rules?
The bottom line
LL-37 is part of human defence against infection. As a drug, it has one positive small trial, one larger trial that found no overall benefit, a foot-ulcer study with mixed outcomes and an open-label COVID-19 result with a different product. FDA has flagged immunogenicity, impurity, male-reproduction and tumour-promotion concerns, and it will be reviewed by the compounding advisory committee before the end of February 2027. Until then, and after, it is not an approved medicine.
Frequently asked questions
What is LL-37?
The only human cathelicidin, a 37-amino-acid antimicrobial peptide made by skin, gut and other tissues that kills microbes and signals to the immune system.
Does LL-37 heal wounds?
A 34-patient leg-ulcer trial was promising, but the 148-patient HEAL LL-37 trial did not significantly improve healing overall. A diabetic foot ulcer trial reported better granulation.
Is LL-37 FDA-approved?
No. FDA lists safety concerns for compounded LL-37 and plans a compounding advisory committee review before the end of February 2027.
What are LL-37's risks?
FDA cites possible immunogenicity, impurity complexities and nonclinical findings suggesting harm to male reproduction and tumour promotion. Excess cathelicidin also drives rosacea inflammation.
When is the PCAC meeting on LL-37?
FDA's page (content current as of April 15, 2026) says before the end of February 2027, to be scheduled in the coming months; no date was posted when we checked on October 27, 2026.
Related on Grey Peptides
Sources
- Lee, M., et al. (2015). Human antimicrobial peptide LL-37 induces glial-mediated neuroinflammation. Biochem Pharmacol, 94(2), 130-41. PMID: 25686659
- Vandamme, D., et al. (2012). A comprehensive summary of LL-37, the factotum human cathelicidin peptide. Cell Immunol, 280(1), 22-35. PMID: 23246832
- Chromek, M., et al. (2006). The antimicrobial peptide cathelicidin protects the urinary tract against invasive bacterial infection. Nat Med, 12(6), 636-41. PMID: 16751768
- Grönberg, A., et al. (2014). Treatment with LL-37 is safe and effective in enhancing healing of hard-to-heal venous leg ulcers: a randomized, placebo-controlled clinical trial. Wound Repair Regen, 22(5), 613-21. PMID: 25041740
- Mahlapuu, M., et al. (2021). Evaluation of LL-37 in healing of hard-to-heal venous leg ulcers: A multicentric prospective randomized placebo-controlled clinical trial. Wound Repair Regen, 29(6), 938-950. PMID: 34687253
- Miranda, E., et al. (2023). Efficacy of LL-37 cream in enhancing healing of diabetic foot ulcer: a randomized double-blind controlled trial. Arch Dermatol Res, 315(9), 2623-2633. PMID: 37480520
- Zhao, Y., et al. (2023). Efficacy and safety of Oral LL-37 against the Omicron BA.5.1.3 variant of SARS-COV-2: A randomized trial. J Med Virol, 95(8), e29035. PMID: 37605995
- Yamasaki, K., et al. (2007). Increased serine protease activity and cathelicidin promotes skin inflammation in rosacea. Nat Med, 13(8), 975-80. PMID: 17676051
- Weber, G., et al. (2009). Human antimicrobial protein hCAP18/LL-37 promotes a metastatic phenotype in breast cancer. Breast Cancer Res, 11(1), R6. PMID: 19183447
- Shih, C. C., et al. (2023). Antimicrobial peptide cathelicidin LL-37 preserves intestinal barrier and organ function in rats with heat stroke. Biomed Pharmacother, 161, 114565. PMID: 36958193
- Lande, R., et al. (2007). Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide. Nature, 449(7162), 564-9. PMID: 17873860
- Ten Bergen, L. L., et al. (2020). Current knowledge on autoantigens and autoantibodies in psoriasis. Scand J Immunol, 92(4), e12945. PMID: 32697368
- U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (cathelicidin LL-37, in the table of nominations withdrawn by the nominators). Content current as of April 22, 2026; read October 1, re-read October 27, 2026. FDA
- U.S. Food and Drug Administration. Meeting of the Pharmacy Compounding Advisory Committee (cathelicidin LL-37, GHK-Cu, dihexa acetate, melanotan II, PEG-MGF; before the end of February 2027). Content current as of April 15, 2026; read October 27, 2026. FDA
- U.S. Food and Drug Administration. July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee ("Advisory committees make non-binding recommendations to the FDA"). Content current as of August 6, 2026; read October 27, 2026. FDA
- Yamshchikov, A. V., et al. (2010). Vitamin D status and antimicrobial peptide cathelicidin (LL-37) concentrations in patients with active pulmonary tuberculosis. Am J Clin Nutr, 92(3), 603-11. PMID: 20610636
- World Anti-Doping Agency. The 2026 Prohibited List, section S0 (LL-37 not named). Read October 27, 2026. WADA
Educational information, not medical advice. Each dose in this guide names its source, an approved label or a published study. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for “research use only” are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose.
New guides and rule changes, by email
One short email when a peptide's legal status moves — an FDA or PCAC decision, a WADA list change, an enforcement action — plus new guides and tools. At most one a week, and none when nothing changes. The newsletter has not started sending yet: your first email will be its first issue.
We keep your email address and the page you signed up from, nothing else. How it works · Privacy · RSS instead